Cooper Ronald Harold Wilfred's Form 4 filing
Albireo Pharma, Inc. (ALBO) · filed Oct 25, 2022
- Accession no.
- 0001209191-22-054485
- Filed
- Oct 25, 2022
- Trade date
- Oct 24, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market sales total $18.0K. It was filed 1 day after the trade.
This filing was later replaced by the amendment 0001209191-23-002632 (Jan 9, 2023). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cooper Ronald Harold WilfredCIK 0001676880 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 24, 2022 | Common Stock | SSaleDisposed | −919 | $19.58 | −$17,994.02 | 55,461 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.